Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01561521 · ClinicalTrials.gov registry record · Phase 3
An Evaluation of the Onset and Duration of Action of AKF-1 Ophthalmic Solution in Treating Acute Allergic Conjunctivitis
A Phase 3 study of Allergic Conjunctivitis, sponsored by Akorn.
- Completed
- Registry status
- Phase 3
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT01561521: Completed Phase 3 study of Allergic Conjunctivitis, sponsored by Akorn.
NCT01561521 is a Phase 3 study of Allergic Conjunctivitis that has completed, run by Akorn. The registered enrollment target is 90 participants, below the 130-participant average among 20 other Allergic Conjunctivitis trials with a reported enrollment target (31% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01561521, a Phase 3 study of Allergic Conjunctivitis, has completed, sponsored by Akorn.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the onset and duration of action of two concentrations of AKF-1 Ophthalmic Solution compared to vehicle in the conjunctival allergen challenge (CAC) model of acute allergic conjunctivitis.
Conditions Studied
Interventions
- DRUG AKF-1
Study Locations (1)
Massachusetts
- Andover Eye Associates - Andover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2012-03 |
| Est. Completion | 2012-04 |
| Phase | Phase 3 |
What the finished NCT01561521 record still lists
NCT01561521 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 130-participant average among 20 other Allergic Conjunctivitis trials with a reported enrollment target (31% lower).
The record links to 1 condition, with Allergic Conjunctivitis appearing as the primary indexed condition, and to 1 intervention - of which AKF-1 is the first listed.
NCT01561521 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01561521 about?
NCT01561521 is a clinical study titled "An Evaluation of the Onset and Duration of Action of AKF-1 Ophthalmic Solution in Treating Acute Allergic Conjunctivitis". The purpose of this study is to evaluate the onset and duration of action of two concentrations of AKF-1 Ophthalmic Solution compared to vehicle in the conjunctival allergen challenge (CAC) model of acute allergic conjunctivitis.
What is the current status of trial NCT01561521?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 90 participants. The study started on 2012-03. Estimated completion is 2012-04.
What conditions does trial NCT01561521 study?
This clinical trial studies the following conditions: Allergic Conjunctivitis.
What interventions are being tested in trial NCT01561521?
The interventions under investigation include: AKF-1 (DRUG).
Who is sponsoring clinical trial NCT01561521?
This trial is sponsored by Akorn, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01561521 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Allergic Conjunctivitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01561521's enrollment target sits among peer trials
90 13th of 20 higher than 8 of 20 other Allergic Conjunctivitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Allergic Conjunctivitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen Allergy
RECRUITING · Phase 3
-
Evaluation of Efficacy of Ophthalmic Solution in Induced Allergic Conjunctivitis
COMPLETED · Phase 3
-
ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis
COMPLETED · Phase 3
-
A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle
COMPLETED · Phase 3
-
Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution
COMPLETED · Phase 3
-
Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis.
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia